
US$240 (10 mg / vial, lyophilized). Delivery in 2–4 business hours in Santo Domingo at no charge; rest of the Dominican Republic in 6–12 h (RD$400). Janoshik COA linked below. Research use only.
FDA-approved synthetic GHRH analog — the only peptide with specific indication for visceral abdominal fat reduction.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Tesamorelin is a synthetic analog of full-length human GHRH, all 44 amino acids, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. That small hydrophobic modification blocks the DPP-4 cleavage that inactivates natural GHRH within minutes, and it is the reason tesamorelin has a 25-to-40-minute half-life and more sustained activity than sermorelin. It was developed by Theratechnologies (Montreal).
Like all GHRH analogs it stimulates pulsatile GH secretion through its pituitary receptor and raises IGF-1 in a manner dependent on an intact axis. What sets it apart is its clinical base: two Phase 3 trials in more than 800 people with HIV and abdominal fat accumulation showed a CT-measured reduction in visceral adipose tissue of around 15–18% at 26 weeks, reversing on discontinuation (Falutz et al., NEJM 2007 and JCEM 2010). A later trial described a reduction in liver fat in the same population (Stanley et al., Lancet HIV 2019).
On that evidence the FDA approved the molecule in 2010 as Egrifta, with the specific indication of reducing excess abdominal fat in HIV-associated lipodystrophy; it is not approved for any other use. The drug label records IGF-1 elevation, glucose disturbances, fluid retention and arthralgia, and contraindicates it in pregnancy and active malignancy. The product Renova distributes is not Egrifta: it is tesamorelin for research, independently verified and not suitable for human use.
| Class | Stabilized GHRH(1-44) analog |
| Structure | Human GHRH(1-44)-NH2 with a trans-3-hexenoyl group on Tyr1 (44 aa) |
| CAS | 218949-48-5 |
| Reported half-life | ≈ 25–40 minutes (DPP-4 resistant) |
| Phase 3 data | Visceral adipose tissue reduced ≈ 15–18% at 26 weeks in HIV lipodystrophy (NEJM 2007; JCEM 2010) |
| Regulatory status | Molecule FDA-approved as Egrifta (2010) for HIV lipodystrophy; Renova product is RUO |
| Drug-label considerations | IGF-1 elevation, glucose, fluid retention; contraindicated in pregnancy and active malignancy |
| Stability | Lyophilized powder stable when cold; reconstituted solution must stay refrigerated |
A hexenoyl group at the N-terminus. Natural GHRH is inactivated by the DPP-4 enzyme within minutes; that modification blocks the cut and multiplies the molecule's duration. The 44-amino-acid sequence is the same as the human hormone's.
As Egrifta, the FDA approved it in 2010 solely to reduce excess abdominal fat in people with HIV and lipodystrophy. It holds no approval for any other indication. Renova's material is for research and is not that medicine.
In two trials with more than 800 participants with HIV, CT-measured visceral adipose tissue fell by about 15–18% at 26 weeks versus placebo, with no relevant change in subcutaneous fat; the effect reversed when treatment stopped. A 2019 trial additionally described a reduction in liver fat in that population.
Two GHRH analogs with different duration: sermorelin is the native 1-29 fragment and lasts 10–20 minutes; tesamorelin is the stabilized full sequence and lasts more than twice as long, with Phase 3 clinical backing. Our guide on tesamorelin and visceral fat details the differences.
Related reading: Tesamorelin: GHRH Analog and Visceral Fat · CJC-1295 + Ipamorelin: The Most-Studied GH Stack
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty